Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

9.45USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$9.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
92,108
52-wk High
$26.00
52-wk Low
$9.05

Latest Key Developments (Source: Significant Developments)

Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91
Wednesday, 9 May 2018 07:30am EDT 

May 9 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.91.Q1 EARNINGS PER SHARE VIEW $-0.91 -- THOMSON REUTERS I/B/E/S.ON TRACK FOR A Q1 2019 OMADACYCLINE U.S. LAUNCH.PREPARING FOR ADVISORY COMMITTEE MEETING, EXPECTED IN LATE SUMMER 2018, TO REVIEW OMADACYCLINE APPLICATIONS.PARATEK - AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $184.3 MILLION.PARATEK PHARMACEUTICALS - CURRENTLY EXPECTS TO BE ABLE TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS THROUGH Q1 2021.  Full Article

Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78
Thursday, 1 Mar 2018 07:00am EST 

March 1 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019.Q4 LOSS PER SHARE $0.78.Q4 EARNINGS PER SHARE VIEW $-0.75 -- THOMSON REUTERS I/B/E/S.AS OF DECEMBER 31, 2017, PARATEK HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $151.7 MILLION‍​.  Full Article

Paratek Completes Submission Of New Drug Applications To U.S.FDA
Monday, 5 Feb 2018 07:30am EST 

Feb 5 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS.  Full Article

FDA Accepts New Drug Application For Seysara (Sarecycline)
Wednesday, 20 Dec 2017 04:30pm EST 

Dec 20 (Reuters) - Allergan Plc ::FDA ACCEPTS NEW DRUG APPLICATION FOR SEYSARA™ (SARECYCLINE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE.PARATEK PHARMACEUTICALS INC - ALLERGAN EXPECTS PRESCRIPTION DRUG USER FEE ACT ACTION DATE TO OCCUR IN SECOND HALF OF 2018.  Full Article

Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln
Friday, 1 Dec 2017 06:22am EST 

Dec 1 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​.  Full Article

Paratek Pharmaceuticals Q3 loss per share $0.77
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Paratek Pharmaceuticals Inc ::Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018.Q3 loss per share $0.77.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.Paratek Pharmaceuticals - ‍cash, cash equivalents and marketable securities sufficient to fund operating expenses, Capex requirements through Q2 2019​.  Full Article

Paratek Pharmaceuticals Inc Q2 loss per share $0.66
Wednesday, 2 Aug 2017 07:00am EDT 

Aug 2 (Reuters) - Paratek Pharmaceuticals Inc :Paratek Pharmaceuticals, Inc. Reports second quarter 2017 financial results and provides clinical update.Paratek Pharmaceuticals Inc qtrly license and royalty revenue $7.5 million, qtrly loss per share $0.66.Paratek Pharmaceuticals -based on current assumptions, to be able to fund operating expenses and capital expenditure requirements through q2 of 2019.  Full Article

Paratek Pharmaceuticals Q2 loss per share $0.66
Wednesday, 2 Aug 2017 06:37am EDT 

Aug 2 (Reuters) - Paratek Pharmaceuticals Inc :Q2 loss per share $0.66 - sec filing.Q2 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S.  Full Article

Paratek says Omadacycline showed high clinical success rates for infections by Absssi pathogens
Monday, 17 Jul 2017 05:04pm EDT 

July 17 (Reuters) - Paratek Pharmaceuticals Inc :Says phase 3 study of oral-only dosing of Omadacycline met all primary, secondary endpoints in acute bacterial skin infections.Omadacycline generally safe, well tolerated; showed high clinical success rates for infections by most common Absssi pathogens.  Full Article

Paratek pharmaceuticals Q1 loss per share $1.14
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Paratek Pharmaceuticals Inc :Paratek pharmaceuticals, inc. Reports first quarter 2017 financial results and provides clinical update.Q1 loss per share $1.14.Q1 earnings per share view $-1.20 -- Thomson Reuters I/B/E/S.As of march 31, 2017, paratek had cash, cash equivalents, and marketable securities of $139.6 million.  Full Article

U.S. FDA panel backs approval of Paratek's antibiotic

A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.